Choice of biologic medicine is a hot topic in Ophthalmology, with new intravitreal biosimilars expected in 2025. Biosimilars could deliver drug acquisition cost savings for the NHS, however Ophthalmology is the busiest outpatient specialty, and treatment choice can potentially influence service capacity and non-drug costs.

This symposium will explore the current context of medical retina care, the evolution of extended treatment intervals for biologic and biosimilar therapies, and what this means for ophthalmology services.

Agenda:

• Introduction - Mr Luke Nicholson, Ms Catherine Thompson
• Biologics, biosimilars, and their place in ophthalmology care delivery - Mr Athanasios Vardarinos
• Ophthalmology budgets in focus - Mr Tomas Cudrnak
• Audience Q&A

This is a promotional symposium organised and funded by Roche Products Ltd for HCPs and other delegates attending CPC 2025. Roche medicines will be discussed. Prescribing information will be available at the meeting

M-GB-00021915 | April 2025